Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 05 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-4.05 Insider Own1.57% Shs Outstand22.73M Perf Week0.00%
Market Cap368.68M Forward P/E- EPS next Y-0.41 Insider Trans0.00% Shs Float22.37M Perf Month2.01%
Income-72.97M PEG- EPS next Q-0.13 Inst Own38.10% Short Float / Ratio0.19% / 0.16 Perf Quarter229.67%
Sales21.89M P/S16.84 EPS this Y96.16% Inst Trans16.08% Short Interest0.04M Perf Half Y214.95%
Book/sh1.77 P/B9.19 EPS next Y10.29% ROA-33.45% Target Price16.00 Perf Year252.76%
Cash/sh5.52 P/C2.94 EPS next 5Y- ROE-71.56% 52W Range3.60 - 16.30 Perf YTD337.20%
Dividend- P/FCF- EPS past 5Y10.62% ROI-64.52% 52W High-0.49% Beta0.55
Dividend %- Quick Ratio2.98 Sales past 5Y248.26% Gross Margin56.91% 52W Low350.43% ATR0.09
Employees166 Current Ratio3.12 Sales Q/Q9.39% Oper. Margin-499.72% RSI (14)83.61 Volatility0.19% 0.31%
OptionableYes Debt/Eq0.60 EPS Q/Q58.23% Profit Margin-333.37% Rel Volume0.19 Prev Close16.22
ShortableYes LT Debt/Eq0.41 EarningsNov 13 BMO Payout- Avg Volume270.76K Price16.22
Recom3.00 SMA200.84% SMA5010.17% SMA200115.10% Volume51,876 Change0.00%
Date Action Analyst Rating Change Price Target Change
Dec-29-21Resumed Cantor Fitzgerald Overweight $12 → $9
Nov-16-21Downgrade JP Morgan Neutral → Underweight
Aug-18-21Downgrade JP Morgan Overweight → Neutral
Mar-02-21Resumed JP Morgan Overweight
Mar-02-21Initiated Stifel Buy $12
Jan-07-21Initiated Cantor Fitzgerald Overweight $16
Jun-01-20Resumed Oppenheimer Outperform
Sep-17-19Initiated Guggenheim Buy $31
Sep-05-19Initiated Barclays Overweight
Dec-17-18Upgrade Goldman Neutral → Buy
Nov-30-23 07:00AM
Nov-13-23 11:04AM
Oct-31-23 07:39AM
Oct-26-23 12:29PM
07:00AM Loading…
Oct-24-23 07:00AM
Oct-17-23 06:03PM
Oct-09-23 07:53AM
Oct-06-23 07:30AM
Oct-05-23 04:04PM
05:33AM Loading…
Sep-27-23 05:33AM
Sep-20-23 04:36AM
Sep-18-23 07:00AM
Aug-31-23 07:00AM
Aug-15-23 01:46PM
Aug-05-23 05:53AM
Aug-03-23 07:00AM
Aug-02-23 09:11AM
Jul-25-23 07:00AM
Jul-05-23 06:25AM
Jun-26-23 07:00AM
May-24-23 07:00AM
May-19-23 01:48PM
07:00AM Loading…
May-18-23 07:00AM
May-16-23 06:02AM
May-15-23 07:00AM
May-10-23 09:55AM
May-09-23 07:50AM
May-03-23 07:00AM
Mar-30-23 07:00AM
Mar-16-23 06:26AM
Mar-13-23 11:51AM
Mar-11-23 09:06AM
Mar-10-23 10:00AM
Mar-06-23 06:05AM
Mar-03-23 07:00AM
Mar-01-23 06:01AM
Feb-27-23 07:00AM
Feb-24-23 07:00AM
Feb-10-23 07:00AM
Feb-08-23 07:00AM
Jan-09-23 07:00AM
Jan-05-23 07:00AM
Dec-12-22 07:00AM
Dec-01-22 07:00AM
Nov-14-22 07:00AM
Nov-08-22 07:00AM
Nov-07-22 07:00AM
Nov-03-22 09:05AM
Oct-10-22 07:00AM
Aug-29-22 07:00AM
Aug-04-22 07:00AM
May-12-22 07:00AM
May-10-22 07:00AM
May-05-22 07:00AM
May-02-22 07:00AM
Apr-11-22 07:00AM
Mar-30-22 12:02PM
Mar-24-22 07:00AM
Mar-03-22 07:00AM
Feb-07-22 07:00AM
Feb-03-22 07:01PM
Jan-21-22 07:00AM
Jan-10-22 07:00AM
Jan-04-22 07:00AM
Nov-18-21 07:00AM
Nov-08-21 11:59AM
Nov-04-21 07:45AM
Oct-13-21 07:00AM
Sep-14-21 06:00AM
Sep-09-21 07:00AM
Sep-08-21 07:00AM
Sep-07-21 07:00AM
Sep-01-21 07:00AM
Aug-09-21 09:06AM
Aug-04-21 07:00AM
Jul-27-21 05:36PM
Jul-01-21 10:35AM
Jun-29-21 11:43AM
May-28-21 08:12PM
May-24-21 09:00AM
May-13-21 07:00AM
May-11-21 01:06PM
May-10-21 10:50AM
Apr-28-21 07:01AM
Mar-07-21 06:59AM
Mar-03-21 09:00AM
Orchard Therapeutics Plc is a biopharmaceutical company, which engages in discovering, acquiring, developing and commercializing gene therapies for patients with rare disorders. The company focuses on its autologous ex vivo gene therapy approach on three therapeutic rare disease franchise areas: primary immune deficiencies, neurometabolic disorders, and hemoglobinopathies. Its portfolio includes Strimvelis, a commercial-stage gamma retroviral-based product for the treatment of Adenosine deaminase deficiency (ADA-SCID). The company was founded by Nicolas Koebel and Andrea Spezzi in August 2018 and is headquartered in London, the United Kingdom.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
THOMAS FRANK ESee RemarksMar 10Option Exercise0.4620,0009,18292,081Mar 14 08:30 AM
THOMAS FRANK ESee RemarksFeb 09Option Exercise0.4620,0009,18272,081Feb 13 08:09 AM